Formulary adoption is a key step in achieving sales pull through starting in 2022, company officials said.
Formulary Watch
Latest News
All News
Advertisement
The therapy, a recombinant version, was developed to address supply and manufacturing issues.
Patients are being offered $500 to make the switch.
A recent study finds that the approval of a biosimilar was associated with a change in the trajectory of net prices.
Data from a phase 2/3 study will be presented in July.
The label for the type 2 diabetes treatment has been updated to include the risk of ketoacidosis and damage to the kidney.
But there is no benefit for patients receiving chemotherapy.
Kite plans to submit a supplemental BLA based on these findings.
The authorization is based on four studies that evaluated Actemra in more than 5,500 hospitalized patients.
Implementation of value-based approaches requires measurement of value, authors said.
Advertisement
Investigators looked at the association of antiparasitic drug prices with prescribing and prescription-filling behaviors and total outpatient treatment costs.
The start-up aims to develop real-world evidence that provides value to patients, insurers, and employers.
The anticancer therapy is now available in 21-count bottles to help accommodate dispensing.
The two organizations have created a fellowship program to help improve patient outcomes and reduce costs.
The longstanding medicine for adults is now approved to treat children 3 months to less than 12 years old with venous thromboembolism.
The therapy would be used to help prevent and treat blood clots in pediatric patients.
Understanding medication utilization patterns is important for future evaluations of clinical outcomes, investigators say.
Novartis’ investigational targeted radioligand therapy extends survival in patients with advanced metastatic prostate cancer.
Adults taking medications that cross the blood-brain barrier had better memory recall.
A longstanding four times per day testing requirement will cease, and patients using inhaled insulin now qualify for continuous glucose monitoring.
Regardless of political affiliation, the public supports congressional action to allow the federal government to negotiate prices.
Although Lorbrena can improve health outcomes, it is not as cost-effective an option compared with Xalkori.
The therapy is a modified poliovirus vaccine that not only kills cancer cells but also can trigger long-term immune memory.
The Supreme Court’s dismissal of the latest challenge means patients will have access to lower-cost therapies, an advocacy group says.
The COX-2 inhibitor Anjeso, a faster-acting injectable formulation of meloxicam, reduces opioid use after surgery.
Chances of left ventricular ejection fraction almost disappeared when patient took the ACE-inhibitor lisinopril during treatment with trastuzumab/anthracycline, according to research presented at ASCO.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Prior authorization isn’t shrinking. Its savings are
2
What employees may miss when they buy drugs directly online
3
PBMI Innovator Arpit Patel, Pharm.D.
4
7 takeaways from the MHE webinar on PBM reform and transparency
5